Obviously hepatocellular carcinoma differs from glioblastoma; the point is not to make a strong claim that this particular mutation contributes to glioblastoma progression, but rather to point out that there is evidence linking mutations that damage CYP4A22 function, as the L194R mutation is predicted to, to cancer progression, indicating further study is warranted. This evidence concerns the gene CYP4A22 and hepatocellular carcinoma.